High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment
about
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Unravelling the biology of SCLC: implications for therapy.Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancerOvercoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors.
P2860
High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
High SLFN11 expression predict ...... nt oxaliplatin-based treatment
@ast
High SLFN11 expression predict ...... nt oxaliplatin-based treatment
@en
type
label
High SLFN11 expression predict ...... nt oxaliplatin-based treatment
@ast
High SLFN11 expression predict ...... nt oxaliplatin-based treatment
@en
prefLabel
High SLFN11 expression predict ...... nt oxaliplatin-based treatment
@ast
High SLFN11 expression predict ...... nt oxaliplatin-based treatment
@en
P2093
P2860
P1433
P1476
High SLFN11 expression predict ...... nt oxaliplatin-based treatment
@en
P2093
Jianping Wang
Xiuping Deng
Yanhong Deng
Zihuan Yang
P2860
P2888
P356
10.1186/S12885-015-1840-6
P407
P577
2015-11-02T00:00:00Z
P5875
P6179
1048486660